Sign in

    Tucker Remmers • Jefferies

    Tucker Remmers's questions to Fortrea Holdings Inc (FTRE) leadership

    Tucker Remmers's questions to Fortrea Holdings Inc (FTRE) leadership • Q2 2025

    Question

    Tucker Remmers of Jefferies asked for the rationale behind the second-half revenue guidance, which implies a step-down from Q2, and the role of pass-throughs. He also inquired about the large pharma environment and Fortrea's win rates with those clients.

    Answer

    CFO Jill McConnell explained that the anticipated revenue moderation is partly due to the successful early conclusion of a large, pass-through-heavy study. She noted that while H2 revenue would be more aligned with Q1 levels, margins are expected to be better due to ongoing cost savings. She also confirmed that relationships and win rates with existing large pharma customers remain strong and consistent.

    Ask Fintool Equity Research AI

    Tucker Remmers's questions to West Pharmaceutical Services Inc (WST) leadership

    Tucker Remmers's questions to West Pharmaceutical Services Inc (WST) leadership • Q2 2025

    Question

    Tucker Remmers from Jefferies inquired about the hurdles to automating the SmartDose device assembly and the potential margin improvement from the new line expected in 2026.

    Answer

    CEO Eric Green stated that the company is on track with its plan, which involves both driving near-term cost improvements and commercializing a new automated line in late 2025 or early 2026. While he declined to comment on specific product-level margins, he assured that the team is focused on enhancing the economics of SmartDose and evaluating all strategic options.

    Ask Fintool Equity Research AI